Clinical trial NCT06726577: TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis
Official title: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial Evaluating the Safety, Efficacy, and Pharmacokinetic Characteristics of TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
PHASE2
Conditions: Amyotrophic Lateral Sclerosis
Lead sponsor: Talengen Institute of Life Sciences, Shenzhen, P.R. China.
Sponsor class: OTHER
Collaborators: name: The First Affiliated Hospital of Soochow University
First posted: 2024-12-10
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This trial adopts a multicenter, randomized, double-blind, placebo-controlled parallel design.

This experiment is divided into two groups: the experimental drug group and the placebo group. Successful participants will be randomly assigned to the two groups, with an expected enrollment of 60 participants. There will be 30 participants in the experimental drug group and 30 participants in the placebo group. During the treatment period, the experimental drug group received intravenous injections of 0.83mL/kg TP04HN106 each time; The placebo group received intravenous injections of 0.83mL/kg of saline each time. During the extension period, all subjects received intravenous injection of 0.83mL/kg TP04HN106. In the experiment, all subjects received Liraglutide tablets as the standard baseline treatment.

The subjects who were successfully screened in the experiment were enrolled in sequence, and the safety, tolerability, efficacy, and pharmacokinetic characteristics of the experimental drug were evaluated after administration. The entire trial includes a screening period of 1 week, a treatment period of 12 weeks (including 3 treatment cycles, each treatment cycle of 4 weeks), an extension period of 12 weeks (including 3 treatment cycles, each treatment cycle of 4 weeks), and a follow-up period of 4 weeks. In addition, some subjects underwent a 1-week single dose PK study before the start of the treatment period; In addition, during the first treatment cycle of the treatment period, some subjects were selected for multiple dosing PK studies.

We plan to conduct a single dose PK study among 12 subjects, with 6 subjects in the experimental group and 6 subjects in the control group; Multiple dose PK studies were conducted among 12 subjects, with 6 subjects in the experimental group and 6 sujects in the control group. It is not allowed for the same subject to participate in both single dose and multiple dose PK studies simultaneously.

The 1st to 12th subjects planned to be enrolled in the trial will undergo a single dose PK study. After the first dose, venous blood will be collected from the 12 subjects according to the blood sample collection requirements, and their PK characteristics will be evaluated. The observation period for single dose administration is one week. After completing the final blood sample collection and safety assessment, the subjects enter the treatment period, extension period, and follow-up period.

The 13th to 24th subjects planned to be enrolled in the trial will undergo multiple dose PK studies. These 12 subjects will have their venous blood collected according to the blood sample collection requirements during the first treatment cycle of the treatment period, and their PK characteristics will be evaluated. After completing the treatment period, the subjects will enter the extension period and follow-up period.


Eligibility criteria: Inclusion Criteria:

1. Meet the diagnostic criteria for amyotrophic lateral sclerosis (ALS) (Gold Coast Criteria 2020）;
2. Age ≥18 years old, male or female;
3. The amyotrophic lateral sclerosis Function Rating Scale (ALSFRS-R）of pre-visit subjects should be ≥1 score for dyspnea, upright breathing and respiratory dysfunction;
4. Pre-randomized subjects received stable dose of riluzole tablets for ≥7 days, and should maintain the treatment until the last study visit;
5. Voluntarily participate in clinical trials, sign informed consent, and understand and comply with study procedures.

Exclusion Criteria:

1. The subject is known to be allergic to the investigational drug or its excipients;
2. The subject has a disease or injury that interferes with functional assessment or threatens life, or is accompanied by a serious irreversible disease of the heart, lung, liver, or brain, or is accompanied by a failure of different organs (for patients with respiratory failure, only patients diagnosed as type I or type II respiratory failure are excluded);
3. The subject has a major mental illness or cognitive dysfunction;
4. Patients with a history of secondary or above surgery within one month before the screening period;
5. The subjects participated in other clinical studies within 1 month;
6. The subjects are pregnant or lactating women;
7. Poor compliance or other researchers believe that there are any circumstances that are not suitable for inclusion.

   -

Primary outcomes:
measure: Amyotrophic Lateral Sclerosis Rating Scale (ALSFRS-R)
timeFrame: Baseline, 10th week
Secondary outcomes:
measure: ALSFRS-R
timeFrame: Baseline, week 2, 6, 12, 14, 18, 22, and 28
measure: Rasch Global Disability Assessment Scale (ROADS) scores
timeFrame: Baseline, week 2, 6, 10, 12, 14, 18, 22, and 28
measure: FVC%
timeFrame: Basline, week 6, 10, 12, 14, 18, 22, and 28
measure: Muscle strength
timeFrame: Baseline，week 2, 6, 10, 12, 14, 18, 22, and 28;weeks 2, 6, 10, 12, 14, 18, 22, and 28
measure: Neurofilament light chain level
timeFrame: Baseline，week 10，week 22
measure: CMAP amplitude
timeFrame: Baseline，week 10，week 22
measure: Incidence of permanent invasive breathing or oxygen assistance/death
timeFrame: Through study completion, an average of 28 weeks
Other outcomes:
Locations:
city: Suzhou
country: China
facility: The First Affiliated Hospital of Soochow University
state: Jiangsu
Study officials:
References: